Drug Profile
Research programme: non-catalytic site HIV integrase inhibitors - Gilead
Alternative Names: GS 9695; GS 9822; Non-catalytic site HIV integrase inhibitors - Boehringer IngelheimLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Gilead Sciences
- Class Anti-infectives; Antivirals
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
- 13 Feb 2017 Adverse events, pharmacodynamic data and pharmacokinetic data from preclinical study in HIV-infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
- 13 Feb 2017 Preclinical development in HIV-infections is ongoing in USA